other material
confidence high
sentiment positive
materiality 0.70
Invivyd announces PEMGARDA neutralizing activity against dominant variants KP.3.1.1 and LB.1
Invivyd, Inc.
- New in vitro data show PEMGARDA neutralizes KP.3.1.1 (42.2% of US cases) and LB.1 variants.
- Pemivibart epitope intact across 99.59% of viral sequences since Omicron BA.1.
- Data submitted to FDA for timely updates to PEMGARDA Fact Sheet.
- Pipeline candidate VYD2311 also shows potent neutralization against contemporary variants.
- Company notes 33 variants tested over two years; addresses preliminary non-peer-reviewed reports questioning activity.